Clinical Trial Update: RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating RD13-02 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• RD13-02 CAR-T cell therapy (RD13-02 CAR-T)

Snippet

Sponsor: Xiaoyu Zhu | Conditions: Neoplasms, Hematologic Neoplasms | EARLY_Phase 1 | Status: COMPLETED